11Jan 2025
Plasma Biomarkers Effectively Differentiate Alzheimer's and FTLD

Plasma Biomarkers Effectively Differentiate Alzheimer's and FTLD

This cohort study with 374 participants (96 Alzheimer's disease (AD), 278 frontotemporal lobar degeneration (FTLD)) evaluates plasma biomarkers for distinguishing AD from FTLD. Plasma phosphorylated tau (p‐tau)217 and the NfL/p‐tau217 ratio were found to effectively differentiate AD from FTLD. The three-range threshold approach demonstrated high sensitivity (95%) and specificity (97.5%), significantly reducing the need for invasive testing, offering a non-invasive diagnostic alternative for AD and FTLD differentiation.

  • #neurology

Like

Save

Share